TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Changing to DuoTrav From Prior Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have a clinical diagnosis of ocular hypertension, primary open-angle or pigment dispersion glaucoma in both eyes.~* Must have an IOP of between 19 to 35 millimeters mercury (mmHg) (at any time of the day) in at least one eye (which would be designated as the study eye).~* Must be willing to discontinue the use of all other ocular hypotensive medication(s) prior to receiving the study medication for the entire course of the study.~* Women who are pregnant or lactating.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Known medical history of allergy, hypersensitivity or poor tolerance to any component of DuoTrav® that is deemed clinically significant in the opinion of the Principal Investigator.~* Corneal dystrophies in either eye.~* Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment.~* Bronchial asthma or a history of bronchial asthma, bronchial hyper-reactivity, or severe chronic obstructive pulmonary disease that would preclude the safe administration of a topical beta-blocker.~* History of severe allergic rhinitis.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DuoTrav (Type: EXPERIMENTAL): One drop in study eye(s) once daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tenofovir in Chronic Hepatitis B With Mild ALT Elevation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 25 to 70 years,~* serum HBsAg positivity for more than 6 months,~* positive or negative serum HBeAg,~* serum HBV DNA more than 2,000 IU/mL,~* highest serum ALT \> 1 fold of ULN, but \< 2 X ULN on at least two occasions (≧ 3 months apart) in the preceding one year,~Exclusion Criteria:~* co-infection with HIV, HCV, or HDV,~* previous exposure to HBV antiviral therapy for more than 12 weeks,~* presence of cirrhosis on histopathology,~* hepatic decompensation defined as serum bilirubin \> 2mg/dl and prolonged prothrombin time \> 3 seconds,~* concurrent malignant diseases including hepatocellular carcinoma,~* severe co-morbidity with life expectancy \< 1year,~* pregnant or lactating women,~* organ transplantation except cornea or hair transplant,~* suspected or confirmed chronic liver diseases from etiologies other than HBV (e.g. alcoholic hepatitis, Wilson disease, Hemochromatosis...etc),~* serum creatinine \>1.5mg/dL

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TDF (Type: EXPERIMENTAL): tenofovir disoproxil fumarate (TDF) 300mg
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed CD20 positive marginal zone B-cell lymphomas~* Ann Arbor stage III or IV~* No prior chemotherapy or radiotherapy for advanced stage MZL~* Tumor response after 8th cycles of R-CVP CTx ≥ SD (Stable disease)~* Performance status (ECOG) ≤ 2~* age ≥ 20~* At least one or more bidimensionally measurable lesion(s): ≥ 2 cm by conventional CT/ ≥ 1 cm by spiral CT/ skin lesion (photographs should be taken) ≥ 2 cm/ measurable lesion by physical examination ≥ 2 cm~* Adequate renal function: serum creatinine level \< 2 mg/dL (177 μmol/L)~* Adequate liver functions: Transaminase (AST/ALT) \< 3 X upper normal value / Bilirubin \< 1.5 X upper normal value /Alkaline phosphatase \< 5 X upper normal value~* Adequate BM functions:ANC \> 1500/uL and platelet \> 75,000/uL and Hemoglobin \> 9.0 g/dL unless abnormalities are due to bone marrow involvement by lymphoma~* Informed consent~Exclusion Criteria:~* Other subtypes NHL than MZL~* Large cell component \>10%~* Tumor response after 8th cycles CTx = PD (Progression disease)~* Central nervous system (CNS) metastasis~* Any other malignancies within the past 5 years except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri~* Pregnant or lactating women, women of childbearing potential not employing adequate contraception~* Other serious illness or medical conditions i. Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry ii. History of significant neurologic or psychiatric disorders including dementia or seizures iii. Active uncontrolled infection (viral, bacterial or fungal infection) iv. Other serious medical illnesses~* Known hypersensitivity to any of the study drugs or its ingredients (i.e., hypersensitivity to Polysorbate 20, CHO cell products, or recombinant human antibodies)~* Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): rituximab 375mg/m2, every 8 weeks, 12 times

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Completed the 12-week treatment period in 1 of the 2 parent studies (Study DMVT-505-3001 or Study DMVT-505-3002);~2. Male and female subjects~3. Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance while on the study, and for at least 4 weeks after the last exposure to study treatment~4. Capable of giving written informed consent~Exclusion Criteria:~1. Used a prohibited concomitant product or procedure to treat psoriasis during parent study~2. Had a serious adverse event (SAE) that was potentially related to treatment or experienced an adverse event (AE) that led to permanent discontinuation of treatment in the parent study~3. History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion, may interfere with the subject's completion of the study~4. Known hypersensitivity to tapinarof

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tapinarof (DMVT-505) Cream Group (Type: EXPERIMENTAL): Subjects who completed 1 of the phase 3 studies evaluating the safety and efficacy of tapinarof had the option to enter this extension study.~Subjects entering with a PGA ≥ 1 received treatment with tapinarof cream, 1% until they achieve a PGA = 0, at which time treatment was discontinued and subjects were monitored for durability of response (remittive response). If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re initiated and continued until a PGA = 0 was achieved.~Subjects entering with a PGA = 0 had treatment discontinued and were monitored for duration of remittive response. If/when disease worsening occurred, as evidenced by a PGA ≥ 2, treatment was re initiated and continued until a PGA = 0 was achieved.~This treatment and re treatment pattern of use was continued until the end of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes for at least 6 months before trial start~* Treatment with at least 1000 mg metformin per day for at least 3 months~* Insulin-naive (short-term insulin treatment of up to 14 days is allowed)~* DPP-4 (dipeptidyl peptidase-4) inhibitor naive~* HbA1c (glycosylated haemoglobin A1c) between 7.5-10.0% by central laboratory analysis~* BMI (Body Mass Index) lesser than or equal to 45.0 kg/m2~* Able and willing to take one subcutaneous injection every day~* Able and willing to perform mandatory SMPG (self measured plasma glucose) measurements~Exclusion Criteria:~* Known or suspected allergy or intolerance to any of the trial products or related products~* Severe hypertension~* Treatment with thiazolidinedione (TZD) or GLP-1 (glucagon-like peptide-1) analogues within 2 months prior to trial start~* Cardiac disease, within the last 12 months~* Impaired hepatic function~* Impaired renal function~* Proliferative retinopathy or macular oedema requiring acute treatment~* Female of childbearing potential~* Known or suspected abuse of alcohol, narcotics or illicit substances

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Comb (Type: EXPERIMENTAL): Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment
- Sita (Type: ACTIVE_COMPARATOR): Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 and ≤ 70 years of age , with ≥ 40Kg~* Histological or cytological confirmed colorectal cancer~* ECOG performance status of 0-1~* Standard regimen failed or no standard regimen available~* Adequate hepatic, renal, heart, and hematologic functions~* At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)~* Signed and dated informed consent.~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure~Exclusion Criteria:~* Pregnant or lactating women~* Any factors that influence the usage of oral administration~* Evidence of CNS metastasis~* Intercurrence with one of the following: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure~* Abuse of alcohol or drugs~* Less than 4 weeks from the last clinical trial~* Previous treatment with VEGFR inhibition~* Disability of serious uncontrolled intercurrence infection~* Proteinuria ≥ 2+ (1.0g/24hr)~* Uncontrolled hemorrhage in GI~* Within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.~* Within 6 months before the first treatment occurs acute myocardial infarction, acute coronary syndrome or CABG~* Bone fracture or wounds that was not cured for a long time~* Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A- 4mg QD (Type: EXPERIMENTAL): arm A- fruquintinib 4mg once daily, p.o.,continuous;given in 28-days cycles until disease progress, intolerable toxicity or patients withdrawal of consent
- B- 5mg once daily, 3wks on/1wk off (Type: EXPERIMENTAL): arm B-fruquintinb 5mg once daily,p.o.,3 weeks on/1 week off, given in 28-day cycles until disease progress,intolerable toxicity or patients withdrawal of consent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, postmenopausal women, aged 40 to 64, with last natural menstrual period completed at lease 6 months ago~* Intact uterus~* Seeking treatment for hot flushes and experiencing 7 moderate to severe hot flushes per day or 50 per week~Exclusion Criteria:~* History of active presence of thrombophlebitis, thrombosis, thromboembolic disorders~* History of active presence of stroke, TIA, heart attack or ischemic heart disease~* History of melanoma, breast or any gynecologic cancer at any time; history of any other cancer within the past 5 years

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Daily smokers (10 cigarettes per day or more);~* Smokers motivated to make a quit attempt within the next 14 days;~* Potential subjects must be outpatients;~* A subject must have a stable mental and physical medical condition (as per investigator's judgment).~Exclusion Criteria:~* A subject currently eligible for smoking cessation treatment (SCT) reimbursement, whether from a public or a private drug insurance;~* A subject with an unknown drug insurance status;~* A subject living in a household where there is someone already recruited in the study;~* A subject with an unfilled SCT prescription issued within the past three months or with an unused SCT product;~* A subject with a life-threatening illness (ie, known or suspected cancer or other disease with a life expectancy of less than one year).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Full Smoking Cessation Treatment Coverage (100%) (Type: OTHER): A subject randomized to the intervention group will be eligible for smoking cessation treatment (SCT) reimbursement during the 26-week period following the randomization.
- No Smoking Cessation Treatment Coverage (0%) (Type: OTHER): Subjects in the control group choosing to quit using an SCT method will not be eligible for smoking cessation treatment (SCT) reimbursement and, thus, will have to purchase their treatment out of pocket.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 and 80 years old.~* With liver cirrhosis diagnosed by previous biopsy or by clinical criteria, and analytical image.~* No esophageal varices (or with small varices without red signs) in a recent videogastroscophy (\<3 months before randomization).~* Absence of ascites demonstrated by a recent ultrasound (\<3 months before the randomization).~* informed consent~Exclusion Criteria:~* previous decompensation of liver cirrhosis associated with portal hypertension.~* GPVH \<10 mmHg.~* Portal axis thrombosis affecting the portal trunk or main hepatic branches, or the splenic or mesenteric vein.~* Hepatocellular carcinoma demonstrated by two imaging tests.~* Bilirubin\> 3 mg / dl (or\> 50 micromol / l), platelets \<30 x10E9/lo Quick \<30%.~* Presence of renal insufficiency (serum creatinine\> 2 mg / dl or\> 200 micromol / l).~* Any comorbidity involving a therapeutic limitation and / or a prognosis of life \<12 months.~* Absolute contraindication to treatment with β-blockers (severe bronchospasm, stenosis aortic A-V block, intermittent claudication, severe psychosis, bronchial asthma)~* Hypersensitivity to β-blockers.~* Pregnancy or lactation.~* To receive anticoagulant treatment.~* Past treatment with nitrated or β-blockers in the two weeks prior inclusion.~* Cirrhosis C virus active antiviral therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Propranolol (Type: EXPERIMENTAL): None
- carvedilol (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have bipolar I disorder, current episode manic or mixed~* Treated with lithium or valproic acid~Exclusion Criteria:~* Have an unstable medical condition~* Clinically significant laboratory abnormality.~* Have a primary diagnosis other than bipolar I disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Asenapine (Type: EXPERIMENTAL): Participants received asenapine as a fast-dissolving sublingual (SL) tablet, given twice daily (BID). On Day 1, participants received asenapine 5 mg, BID. On Days 2 to 84, asenapine was dosed flexibly: BID at either 5 or 10 mg. Asenapine doses were up- or down-titrated based on efficacy, safety, and tolerability.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo on Days 1-84 as a fast-dissolving SL tablet, BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Family Based Mindfulness Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Between ages 18-70 years;~2. Able to read and write (parent)~3. Family with a child between 2-5 years old~4. BMI of parent in obese category~5. High parenting stress (mean score of \>=3 on 3 questions from Parenting Stress Index)~Exclusion Criteria:~1. Any psychotic disorder or current psychiatric symptoms for child or parent requiring specific attention, including active symptoms of psychosis or suicidal/homicidal ideation~2. Diagnosis of mental retardation, autism or other pervasive developmental disorder for child~3. Inability to give informed consent~4. Current serious medical disorder precluding participation in physical activity

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- lifestyle (Type: ACTIVE_COMPARATOR): Attentional control group will receive weekly meeting to view relaxing video and facilitate discussion along with counseling on nutrition and physical activity for 8 weeks.
- therapy (Type: EXPERIMENTAL): Active group will receive weekly mindfulness based parenting stress reduction (PMH) plus nutrition and physical activity counseling for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Aldosterone on Energy Starvation in Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Nonischemic dilated cardiomyopathy~* Left ventricular ejection fraction 35% or less~* Stable heart failure symptoms~* Able to undergo both positron emission tomography and magnetic resonance imaging with gadolinium~* Able to tolerate treatment with spironolactone~Exclusion Criteria:~* Serum potassium \>5.0~* Serum creatinine \>2.5~* Contraindications to magnetic resonance imaging such as internal cardioverter-defibrillator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Results with spironolactone (Type: EXPERIMENTAL): patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete